科研之友
微信
新浪微博
Facebook
分享链接
摘要
Multipronged immunotherapies that activate both T cells and natural killer (NK) cells may result in more robust and durable anticancer responses. The successful outcome of dendritic cell (DC)-based vaccination therapy involves a hitherto unrecognized role for NK cells. Combinatorial regimens that enhance the contribution of NK cells to the anticancer immune response may therefore improve clinical outcomes.
- 出版日期2014-4
